Eli Lilly and Co expected to post earnings of $2.46 a share - Earnings Preview

Reuters04-26

* Eli Lilly and Co is expected to show a rise in quarterly revenue when it reports results on April 30 for the period ending March 31 2024

* The Indianapolis Indiana-based company is expected to report a 28.2% increase in revenue to $8.922 billion from $6.96 billion a year ago, according to the mean estimate from 16 analysts, based on LSEG data.

* ​LSEG's mean analyst estimate for Eli Lilly and Co is for earnings of $2.46 per share.

* The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 21 "strong buy" or "buy," 7 "hold" and no "sell" or "strong sell."

* The mean earnings estimate of analysts had fallen by about 5.5% in the last three months. ​

* Wall Street's median 12-month price target for Eli Lilly and Co is $837.50​, above​ its last closing price of $724.87. ​​​

Previous quarterly performance (using preferred earnings measure in US dollars). ​

QUARTER STARMINESM LSEG IBES ACTUAL BEAT, SURPRI

ENDING ARTESTIMAT ESTIMATE MET, SE %

E® MISSED

Dec. 31 2023 2.22 2.22 2.49 Beat 12.2

Sep. 30 2023 -0.09 -0.13 0.10 Beat 174.3

Jun. 30 2023 1.97 1.98 2.11 Beat 6.6​

Mar. 31 2023 1.69 1.73 1.62 Missed -6.2

​​Dec. 1.76 1.78 2.09 Beat 17.4

31 2022

Sep. 30 2022 1.89 1.92 1.98 Beat 3.3​

Jun. 30 2022 1.72 1.69 1.25 Missed -26

Mar. 31 2022 2.39 2.32 2.77 Beat 19.2

This summary was machine generated April 26 at 13:24 GMT. All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment